Aleve, Vioxx, Celebrex, and Bextra: What You Need To Know About Arthritis Pain Medications
Recent controversy about the safety of pain medications for arthritis has left patients and health care professionals alike confused about which medications are safe to use. In fact, a recent survey by the Boston-based Rippe Lifestyle Institute indicated that many people with arthritis are suffering unnecessarily because they have stopped or reduced their use of pain relievers due to confusion about which drugs are considered safe.
The survey also showed that now, more than ever, those with arthritis need to understand the benefits and possible side effects associated with all arthritis pain medications. In order to do so, people with arthritis, their caregivers and families must be familiar with recent news about the two types of drugs most commonly used to treat arthritis pain - non-selective, non-steroidal anti-inflammatory drugs (NSAIDs), and another group of NSAIDs known as cyclooxygenase-2 (COX-2) specific inhibitors.
COX-2 specific inhibitors vs. Other NSAIDs
COX-2 specific inhibitors are the newest members of the NSAID class of medications. Available by prescription only, they became widely used in recent years to reduce joint pain and swelling. COX-2 specific inhibitors work by selectively blocking, or inhibiting, one of the two enzymes associated with inflammation. Some experts think that this selective inhibition may be one reason for some of the negative side effects currently associated with COX-2 specific inhibitors.
Non-selective NSAIDs were developed earlier than COX-2 specific inhibitors and have been widely used to relieve arthritis pain and inflammation for many years. Unlike COX-2 specific inhibitors, non-selective NSAIDs inhibit both major enzymes involved in the inflammatory process, COX-1 and COX-2. The non-selective NSAID category includes a number of different medications that are available in both prescription and over-the-counter (OTC) products.
Timeline of Events
To understand the current state of affairs, it is important to understand the sequence of events. The controversy started when a study published in the October 21, 2004, issue of the New England Journal of Medicine cited the COX-2 specific inhibitor, Vioxx as potentially causing "major adverse events," including heart attack and stroke, among patients taking the drug. As a result, Merck (the drug's manufacturer) voluntarily withdrew Vioxx from the market. However, in the months following, the safety of the other available COX-2 specific inhibitors such as Celebrex and Bextra, as well as other arthritis pain medications in the non-steroidal anti-inflammatory (NSAID) class, were also called into question.
Consequently, in February 2005, the US Food and Drug Administration (FDA) convened a special Advisory Committee, made up of members of the Arthritis and Drug Safety Advisory Committees, to review the cardiovascular safety of these arthritis pain medications.
FDA Directive: Stronger Warning Labels for Some Pain Medications
On April 7, 2005, taking into account the recommendations of the Advisory Committee, the FDA issued the following directives:
? Bextra, a COX-2 specific inhibitor manufactured by Pfizer, was withdrawn from the market.
? All prescription NSAIDs must revise their labeling to include a "black box" warning that highlights the potential increased risk for cardiovascular (CV) events as well as the potentially life threatening gastrointestinal (GI) bleeding associated with these drugs. Celebrex, the only COX-2 specific inhibitor remaining on the US market, was included in this directive.
? All OTC NSAIDs (except aspirin) will be required to revise their labeling to include more specific information about the potential for GI and CV side effects, a stronger reminder to follow label instructions, as well as a warning about potential skin reactions.
To further evaluate the potential for increased CV risk, the FDA also announced that all NSAIDs must conduct and submit to the FDA a comprehensive review and analysis of pertinent safety data from clinical trials.
? Aleve (naproxen sodium) is supported by clinical studies conducted to gain approval of naproxen as a prescription product and as OTC that do not provide any evidence of increased risk of cardiovascular events.
Treatment Options: What Should Arthritis Patients Know?
For some people who suffer from pain associated with arthritis, their symptoms can be managed with exercise, heat/cold therapy, joint protection, assistive devices, weight control, or in some severe cases, surgery. For others, medications are needed to help manage the symptoms associated with arthritis.
When taken as directed OTC medications such as Aleve provide a safe and effective way to treat mild to moderate pain of minor arthritis. If patients have questions, they should consult their health care professional about which treatment option is most appropriate.
Why It's Important to Treat Arthritis
Arthritis affects approximately 66 million Americans and is the nation's leading cause of disability. There are over 100 different types of arthritis, and they all have different symptoms that vary in severity from person to person. The most common form of arthritis, osteoarthritis, is characterized by the breakdown of cartilage that causes the bones to rub together, resulting in pain, loss of movements and stiffness. Arthritis is usually a chronic condition.
For more information on Aleve and naproxen, visit the Aleve website at www.aleve.com. For more information on arthritis pain relief, visit www.arthritis.org
Please visit http://www.aleve.com for more information.
Latest News
BioImagene CEO, Dr. Ajit Singh, Speaks On Enabling Personalized ... MarketWatch - Digital pathology, a key enabler for personalized medicine, will aid clinicians in managing and interpreting data from a whole new set of diagnostic tests ... Aperio Introduces SecondSlide(TM) Digital Slide Sharing Network |
 Boston Globe | Medicine for the Job Market New York Times, United States - By JONATHAN GRUBER A CENTRAL feature of Barack Obama’s presidential campaign was an aggressive plan to expand health insurance coverage by subsidizing ... New Report Shows Slower Premium Growth, But Increasing Pressure to ... Health Corps Research database from the US Library of Medicine |
 Current World News | American College of Surgeons Comments on Institute of Medicine ... MarketWatch - CHICAGO, Dec 03, 2008 /PRNewswire-USNewswire via COMTEX/ -- The American College of Surgeons (ACS) today recognized the Institute of Medicine (IOM) for its ... BMC Internal Medicine Residency Program Achieves National ... Report urges more sleep for medical residents Medical Residents Must Sleep After 16 Hours, Experts Urge |
Research and Markets: 2008 Integrative Medicine and Dietary ... MarketWatch - In this 32-page issue, we offer a breakdown of 2007 US Complementary and Alternative Medicine sales data and provides a detailed analysis of new integrative ... |
 Afrik.com | 34 Nigerian Children Dead From Tainted Medicine Voice of America - By VOA News Nigerian health officials say they are flying in doses of an antidote for a poisoned teething medicine that has now killed 34 infants. ... 'Toxic' syrup kills Nigerian babies Teething mixture kills more Nigerian babies Nigeria infant drug toll hits 34, antidote flown in |
Research database from the US Library of Medicine The Plain Dealer - cleveland.com, OH - Search PubMed, Clinicaltrials.gov, the CDC and a dozen other medical sites - all at once. AP MEDICAL VIDEO by Michael O'Malley and Joan Mazzolini/Plain ... |
A New Index of Preventive Medicine Companies Motley Fool - The accompanying table [click to enlarge] presents statistics and the top 15 rated companies in the ETF Innovators [ETFI] Preventive Medicine Index. ... |
American Academy of Dermatology Issues Position Statement on Vitamin D MarketWatch - The currently recommended adequate intake levels established by the Institute of Medicine may be revised upward due to evolving research on the increasing ... |
NIGERIA: Jos displaced grapple with food, water, medicine shortages IRINnews.org, NY - JOS, 4 December 2008 (IRIN) - Water, medicine and food supplies are running low for an estimated 10000 people displaced by violence in Jos, northern Nigeria ... |
 Canada.com | "Rogue" stem cell clinics exploit hope: report Reuters - "The direct-to-consumer portrayal of stem cell medicine is optimistic and unsupported by published evidence," Timothy Caulfield of the University of Alberta ... Scientists warn of “rogue” online stem cell clinics Internet stem-cell clinics 'exploiting' MS and Parkinson's patients The International Society for Stem Cell Research Releases New ... |
Resources
-
Sorry Currently Unavailable